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Abstract
The role of Streptococcus species as an aetiological microorganism of vertebral osteomyelitis (VO) is considered to be of little relevance. We
aimed to describe a large number of cases of streptococcal vertebral osteomyelitis (SVO), to analyze the clinical features associated with
different Streptococcus species, and to compare them with a cohort of patients with VO caused by Staphylococcus aureus. An incidence study
and a retrospective, multicenter, observational clinical study of cases of SVO (1991–2011) were performed. Statistical comparison of SVO
by different species and between them and staphylococcal VO was carried out. Over the whole period there was an increasing incidence in
the number of VOs and SVOs per year (p <0.05). Among 58 cases of SVO, those caused by non-viridans streptococcus (Streptococcus
pneumoniae, Streptococcus agalactiae and Streptococcus pyogenes; n = 26) mimicked VO by S. aureus, and presented with more fever,
neurological symptoms and paravertebral abscesses in comparison with those caused by the viridans group (remaining species). In contrast,
the latter have a sub-acute clinical picture and were associated with the presence of endocarditis (p <0.05). Among non-viridans SVOs,
concomitant infection was specifically related to S. pneumoniae (p <0.05). In conclusion, SVO presents a wide range of clinical patterns. The
relationship between VO and diagnosis of endocarditis was established with SVO caused by the viridans group. Whereas non-viridans SVO
mimics acute characteristics of VO caused by S. aureus, cases of viridans SVO are significantly more likely to have a sub-acute clinical
presentation. The increased incidence of SVO during the last decades could support a new epidemiological scenario.
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Abstract
Bacterial contamination of blood components such as ex vivo-stored platelets is a major safety risk in transfusion medicine. We have recently
shown that synthetic antimicrobial peptides named PD1–PD4 derived from the thrombin-induced human platelet-derived antimicrobial
proteins, and repeats of Arg-Trp (RW1–RW5) demonstrate microbicidal activity against selected bacteria and viruses. In the present study,
we selected PD3, PD4, RW2, RW3 and RW4 and evaluated each individual peptide and their various combinations to see whether the
cocktail regimen enhances the antimicrobial activity above and over the individual peptides. Stored platelet or plasma samples spiked with
known titres of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and Bacillus
cereus were treated with either individual peptides or with peptides in various combinations. Analyses revealed that individual peptides show
moderate microbicidal activity (10- to 100-fold reduction) against the tested bacteria relative to their combined regimen. The peptide
combinations (RW2 + RW4, RW2 + RW3 + RW4 and PD4 + RW3 + RW4) on the other hand enhanced the microbicidal activity
(c.10 000-fold reduction) and revealed a minimal inhibitory concentration of 5 lM. Time-kill kinetics indicated that these three peptide
combinations exhibited enhanced antimicrobial activity bringing about a 100-fold reduction of bacterial titres within 20 min of incubation.
The present study therefore demonstrates the synergistic effect of antimicrobial peptides when used in combinations and provides a
proof-of-concept of its potential application as a molecular tool towards pathogen reduction and further extends the possibility of using
peptide combinatorial therapeutics as broad-spectrum antibiotics or as alternatives to combat drug-resistant bacteria.
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